CD274 and breast carcinoma: Atezolizumab (Tecentriq), a PD-L1 inhibitor, has been approved for use in combination with nab-paclitaxel for TNBC, while durvalumab (Imfinzi) and avelumab (Bavencio) are under investigation for their effectiveness in breast cancer.